Mitotic Recombination in Patients with Ichthyosis Causes Reversion of Dominant Mutations in KRT10

Department of Dermatology, Yale University School of Medicine, New Haven, CT 06510, USA.
Science (Impact Factor: 33.61). 10/2010; 330(6000):94-7. DOI: 10.1126/science.1192280
Source: PubMed


Somatic loss of wild-type alleles can produce disease traits such as neoplasia. Conversely, somatic loss of disease-causing
mutations can revert phenotypes; however, these events are infrequently observed. Here we show that ichthyosis with confetti,
a severe, sporadic skin disease in humans, is associated with thousands of revertant clones of normal skin that arise from
loss of heterozygosity on chromosome 17q via mitotic recombination. This allowed us to map and identify disease-causing mutations
in the gene encoding keratin 10 (KRT10); all result in frameshifts into the same alternative reading frame, producing an arginine-rich C-terminal peptide that redirects
keratin 10 from the cytokeratin filament network to the nucleolus. The high frequency of somatic reversion in ichthyosis with
confetti suggests that revertant stem cell clones are under strong positive selection and/or that the rate of mitotic recombination
is elevated in individuals with this disorder.

Download full-text


Available from: Keith A Choate, Sep 19, 2014
  • Source
    • "In some instances, the revertants' expansion is so efficient that selective advantage has been proposed (Choate et al., 2010). Intriguingly, ichthyosis with confetti, a skin disease characterized by confetti-like appearance of revertant skin spots, is associated with a mutation in Keratin 10 (Choate et al., 2010), which, due to its nucleolar mislocalization, could affect ribosome production similar to M À/+ mutants. Thus, based on our findings, it is tentative to speculate that selective advantage in mosaic revertants could in some cases be driven by cell competition. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Throughout their lifetime, cells may suffer insults that reduce their fitness and disrupt their function, and it is unclear how these potentially harmful cells are managed in adult tissues. We address this question using the adult Drosophila posterior midgut as a model of homeostatic tissue and ribosomal Minute mutations to reduce fitness in groups of cells. We take a quantitative approach combining lineage tracing and biophysical modeling and address how cell competition affects stem cell and tissue population dynamics. We show that healthy cells induce clonal extinction in weak tissues, targeting both stem and differentiated cells for elimination. We also find that competition induces stem cell proliferation and self-renewal in healthy tissue, promoting selective advantage and tissue colonization. Finally, we show that winner cell proliferation is fueled by the JAK-STAT ligand Unpaired-3, produced by Minute(-/+) cells in response to chronic JNK stress signaling. Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
    Developmental Cell 07/2015; 34(3). DOI:10.1016/j.devcel.2015.06.010 · 9.71 Impact Factor
  • Source
    • "In skin, every distinct revertant spot or patch has arisen from one single reversion event. The reversion mechanism for KRT10 in ichthyosis with confetti seems to be mitotic recombination (Choate et al., 2010; Burger et al., 2012). The cause for the same mechanism in each revertant spot was thought to be the result of mutant keratin 10 protein forming aggregates in the nucleus, and it was predicted that this mis-localization contributed to the high frequency of reversion seen in the patients. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Revertant mosaicism (RM) refers to the co-existence of cells carrying disease-causing mutations with cells in which the inherited mutation is genetically corrected by a spontaneous event. It has been discovered in an increasing number of heritable skin diseases: ichthyosis with confetti and different subtypes of epidermolysis bullosa. This "natural gene therapy" phenomenon manifests as normal appearing skin areas surrounded by affected skin. Although initially thought to be rare, RM is now considered relatively common in genetic skin diseases. To address the issues relevant to RM, we here discuss the following questions: 1) What is the incidence of RM in heritable skin diseases? 2) What are the repair mechanisms in RM? 3) When do the revertant mutations occur? 4) How do you recognize revertant skin? 5) Do the areas of RM change in size? The answers to these questions allow us to acquire knowledge on these reverted cells, the mechanisms of RM, and utility of the reverted cells to the advantage of the patient. The revertant skin could potentially be used to treat the patient's own affected skin.
    Discovery medicine 09/2012; 14(76):167-79. · 3.63 Impact Factor
  • Source
    • "Another group showed that ichthyosis with confetti, a severe, sporadic skin disease in humans, is associated with thousands of revertant clones of normal skin that arose from spontaneous loss via mitotic recombination of a region on chromosome 17q containing disease-causing mutations in the gene encoding keratin 10 (KRT10). They further suggested that either the revertant stem cell clones are under strong positive selection and/or that the rate of mitotic recombination is elevated in individuals with this disorder [54]. To complicate matters further, another group showed that retrotransposition of long interspersed nuclear elements-1 (LINE-1 or L1s), which are abundant retrotransposons that comprise approximately 20% of mammalian genomes, during brain development can have an impact on gene expression and neuronal function, thereby increasing brain-specific genetic mosaicism. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The pace of exome and genome sequencing is accelerating, with the identification of many new disease-causing mutations in research settings, and it is likely that whole exome or genome sequencing could have a major impact in the clinical arena in the relatively near future. However, the human genomics community is currently facing several challenges, including phenotyping, sample collection, sequencing strategies, bioinformatics analysis, biological validation of variant function, clinical interpretation and validity of variant data, and delivery of genomic information to various constituents. Here we review these challenges and summarize the bottlenecks for the clinical application of exome and genome sequencing, and we discuss ways for moving the field forward. In particular, we urge the need for clinical-grade sample collection, high-quality sequencing data acquisition, digitalized phenotyping, rigorous generation of variant calls, and comprehensive functional annotation of variants. Additionally, we suggest that a 'networking of science' model that encourages much more collaboration and online sharing of medical history, genomic data and biological knowledge, including among research participants and consumers/patients, will help establish causation and penetrance for disease causal variants and genes. As we enter this new era of genomic medicine, we envision that consumer-driven and consumer-oriented efforts will take center stage, thus allowing insights from the human genome project to translate directly back into individualized medicine.
    Genome Medicine 07/2012; 4(7):58. DOI:10.1186/gm359 · 5.34 Impact Factor
Show more